RohitMedicalDeviceResearch

The “ Global Renal Denervation Market Is Anticipated to Touch USD 2,850 Million At A Whopping 40.4% CAGR During the Estimated Years (2018-2023) ”. Market Synopsis (RDN) Renal denervation is a minimally invasive method that helps to treat resistant hypertension. This is a condition where high blood pressure does not respond to medication. Some of the common causes associated to renal hypertension include abnormality in the hormone which control blood pressure, sleep problems especially obstructive sleep apnea, excessive consumption of alcohol, obesity and artery-clogging plaque accumulation in the blood vessels. This procedure aids to cut down blood pressure which is difficult to control through medication. Thus, this reduces the risk of kidney disease, heart failure, heart attack, stroke and death significantly. The RDN procedure utilizes radiofrequency ablation that helps to burn the nerves present in the renal arteries that reduces the nerve activity and this in turn decrease...

Global Renal Denervation Market is majorly driven by the rising prevalence of hypertension across the world. According to the CDC, the prevalence of hypertension was close to 26% among adults aged 20 years or more in 2000. There has been a 5.2% increase in the prevalence of hypertension over the next ten years, making it a prime concern for the healthcare sector in countries across the globe Global Renal Denervation Market is expected to rise at a solid CAGR of 40.4% over the 2018-2023 forecast period, according to a new research report from Market Research Future (MRFR). The market’s value is expected to rise from USD 200 million in 2017 to USD 2,850 million in 2023. Competitive Analysis: Leading players in the global renal denervation market include Boston Scientific, Medtronic, ReCor Medical, Jude Medical, Cardiosonic, Cordis, Kona Medical, Sound Intervention, and Terumo. Inquire for Sample Copy of this Report  https://www.marketresearchfuture.com/sample_requ...